Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eplerenone (GD Searle & Co).

J Martin1, H Krum

  • 1Monash University, Alfred Hospital, Prahran, Victoria, Australia. J.Martin@alfred.org.au

Current Opinion in Investigational Drugs (London, England : 2000)
|September 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Soluble vascular endothelial growth factor receptor-1 is reduced in patients with resistant hypertension after renal denervation.

Journal of human hypertension·2016
Same author

Effectiveness of Catheter-Based Renal Denervation for Treatment Resistant Hypertension - Results of a Systematic Review and Meta-Analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Prevalence of Severe Treatment Resistant Hypertension and Eligibility for Catheter-Based Renal Denervation in Australia - a Preliminary Analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Cost Effectiveness of Catheter-Based Renal Denervation for Treatment Resistant Hypertension - an Australian Payer Perspective.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

The effect of renal denervation on endothelial function and inflammatory markers in patients with resistant hypertension.

International journal of cardiology·2015
Same author

Author reply: To PMID 22909211.

Internal medicine journal·2013
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Eplerenone, an aldosterone receptor antagonist, is being studied for renal disease, heart failure, and hypertension. Phase III trials are evaluating its potential to reduce mortality in post-heart attack patients with heart failure.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Eplerenone is an aldosterone receptor antagonist developed by Searle.
  • It is being investigated for potential therapeutic applications in renal disease, congestive heart failure, and hypertension.

Purpose of the Study:

  • To evaluate the efficacy of eplerenone in reducing mortality rates.
  • To assess the role of eplerenone in patients experiencing heart failure post-myocardial infarction.

Main Methods:

  • A global Phase III survival trial was initiated in January 2000.
  • The trial enrolled patients in the US and approximately 30 other countries.
  • The study focuses on patients with a recent heart attack and a diagnosis of heart failure.

Related Experiment Videos

Main Results:

  • Eplerenone is currently in Phase III clinical trials.
  • Anticipated launch for the compound is 2002.
  • Pharmacia is expected to file for congestive heart failure indication in 2002.

Conclusions:

  • Eplerenone shows promise as a treatment for cardiovascular and renal conditions.
  • Further results from the ongoing Phase III trial are pending.
  • The drug's potential to improve survival rates in specific patient populations is under investigation.